The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Teladoc Health (TDOC) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Teladoc Health is a member of our Medical group, which includes 885 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. TDOC is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for TDOC's full-year earnings has moved 8.07% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, TDOC has gained about 57.43% so far this year. Meanwhile, the Medical sector has returned an average of 5.71% on a year-to-date basis. As we can see, Teladoc Health is performing better than its sector in the calendar year.
Breaking things down more, TDOC is a member of the Medical Services industry, which includes 31 individual companies and currently sits at #104 in the Zacks Industry Rank. On average, stocks in this group have lost 9.66% this year, meaning that TDOC is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track TDOC. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report
To read this article on Zacks.com click here.